Evaluation of Changes in Choroidal and Retinal Thickness after a Single Intravitreal Injection of Bevacizumab in Patients with Diabetic Macular Edema
Current Medical Issues · 2026-07 · 24 (3) · 375-381
DOI: 10.4103/cmi.cmi_35_26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Medical Issues, online erschienen am 07.07.2026. Verfasst von Prathibha Obed und 3 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are currently the mainstay of management in center-involved diabetic macular edema (ci-DME). However, the role of the choroid in diabetic macular edema (DME) and the effect of these drugs on the choroid is not well-understood. The aim of the study was to evaluate the changes in choroidal and retinal thickness after a single intravitreal injection of bevacizumab in patients with ci-DME. Methodology: This was a prospective, observational, hospital-based study at a tertiary care center in South India. Patients with ci-DME in one or both eyes were recruited after obtaining informed consent. Choroidal and retinal thickness was measured using swept source optical coherence tomography at baseline and 2 weeks after a single intravitreal bevacizumab (IVB) injection in the study eye.
Results
A total of 28 patients (56 eyes) were included. There was a statistically significant improvement in logMAR best-corrected visual acuity (0.44 ± 0.23 vs. 0.38 ± 0.22, P = 0.029), with a reduction in subfoveal choroidal thickness (295.05 ± 65.80 vs. 285.93 ± 71.84, P = 0.014) and central retinal thickness (445.64 ± 105.80 vs. 383.11 ± 103.91, P = 0.002) in the treated eye, 2 weeks after a single IVB.
Conclusions
A single intravitreal injection of bevacizumab (IVB) resulted in a significant reduction in both choroidal and retinal thickness, translating to an improvement in vision in treated eyes with ci-DME as early as 2 weeks, which seems to be effective in combating the harmful consequences of VEGF overaction in both the choroid and retina in patients with DME.
Zitieren
APA
Obed, P., Thomas, S., Rebekah, G., & John, S. S. (2026). Evaluation of Changes in Choroidal and Retinal Thickness after a Single Intravitreal Injection of Bevacizumab in Patients with Diabetic Macular Edema. Current Medical Issues, 24(3), 375-381. https://doi.org/10.4103/cmi.cmi_35_26
Vancouver
Obed P, Thomas S, Rebekah G, John SS. Evaluation of Changes in Choroidal and Retinal Thickness after a Single Intravitreal Injection of Bevacizumab in Patients with Diabetic Macular Edema. Current Medical Issues. 2026;24(3):375-381. doi:10.4103/cmi.cmi_35_26
BibTeX
@article{Obed2026,
author = {Obed, Prathibha and Thomas, Sneha and Rebekah, Grace and John, Sheeja Susan},
title = {Evaluation of Changes in Choroidal and Retinal Thickness after a Single Intravitreal Injection of Bevacizumab in Patients with Diabetic Macular Edema},
journal = {Current Medical Issues},
year = {2026},
volume = {24},
number = {3},
pages = {375--381},
doi = {10.4103/cmi.cmi_35_26}
}
EUVIMED